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Abstract 
Background: Relapsed and refractory sarcomas continue to have poor survival rates. The cancer stem cell (CSC) 
theory provides a tractable explanation for the observation that recurrences occur despite dramatic responses to 
upfront chemotherapy. Preclinical studies demonstrated that inhibition of the mechanistic target of rapamycin 
(mTOR) sensitizes the CSC population to chemotherapy.
Methods: Here we present the results of the Phase II portion of a Phase I/II clinical trial that aimed to overcome the 
chemoresistance of sarcoma CSC by combining the mTOR inhibitor temsirolimus (20 mg/m2 weekly) with the chemo‑
therapeutic agent liposomal doxorubicin (30 mg/m2 monthly).
Results: Fifteen patients with relapsed/refractory sarcoma were evaluable at this recommended Phase 2 dose level. 
The median progression free survival was 315 days (range 27–799). Response rate, defined as stable disease or better 
for 60 days, was 53%. Nine of the patients had been previously treated with doxorubicin. Therapy was well tolerated. 
In a small number of patients, pre‑ and post‑ treatment tumor biopsies were available for assessment of ALDH expres‑
sion as a marker of CSCs and showed a correlation between response and decreased ALDH expression. We also found 
a correlation between biopsy‑proven inhibition of mTOR and response.
Conclusions: Our study adds to the literature supporting the addition of mTOR inhibition to chemotherapy agents 
for the treatment of sarcomas, and proposes that a mechanism by which mTOR inhibition enhances the efficacy of 
chemotherapy may be through sensitizing the chemoresistant CSC population. Further study, ideally with pre‑ and 
post‑therapy assessment of ALDH expression in tumor cells, is warranted.
Trial registration The trial was registered on clinicaltrials.gov (NCT00949325) on 30 July 2009. http://www.edito rialm 
anage r.com/csrj/defau lt.aspx
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Background
Therapeutic advances in the treatment of localized high-
grade sarcomas have dramatically improved survival for 
these patients over the past two decades, but patients 
with recurrent or refractory disease continue to have a 
dismal prognosis. Although many high grade sarcomas 
respond well to initial therapy, recurrence is common and 
is usually fatal. The cancer stem cell (CSC) hypothesis 
provides an explanation for the discrepancy between ini-
tial treatment response and overall survival. This model 
proposes that a small subpopulation of chemotherapy-
resistant tumor cells with a “stem cell-like” phenotype is 
responsible for both regrowth of the tumor in its original 
site and/or for metastatic dissemination [1]. Therapies 
that target cancer stem cells would therefore be expected 
to decrease the risk of local and metastatic recurrence, 
dramatically improving the survival of patients with 
high-risk disease.
Cancer cells expressing high levels of aldehyde dehy-
drogenase (ALDH) have been shown to possess a phe-
notype reminiscent of stem cells in numerous cancers 
[2]. In particular, our laboratory has demonstrated that 
Ewing sarcoma cells expressing high levels of ALDH, as 
determined by cell sorting using Aldefluor  (ALDHhigh 
cells), exhibit a variety of stem cell properties, includ-
ing clonogenic growth in soft agar, the ability to grow 
as spheres under non-adherent conditions, and expres-
sion of so-called “stem cell genes” such as OCT4 and 
NANOG [3]. Most importantly, as few as 160  ALDHhigh 
cells can generate a tumor in immune deficient mice, 
as compared with 800,000 unsorted cells. Similar find-
ings have been demonstrated in osteosarcoma and soft 
tissue sarcomas [4, 5]. As predicted by the CSC model, 
 ALDHhigh cells are resistant to doxorubicin and etoposide 
in  vitro when compared with unsorted cells. We subse-
quently demonstrated that inhibition of the mechanistic 
target of rapamycin (mTOR) by sirolimus increases the 
sensitivity of  ALDHhigh cells to doxorubicin and causes 
synergistic cytotoxicity when unsorted cells are treated 
in  vitro [6]. Based on these findings, we conducted a 
Phase I/II study of the combination of liposomal doxoru-
bicin (Doxil) with temsirolimus (Torisel), an intravenous 
mTOR inhibitor that is rapidly converted to sirolimus 
in  vivo, for patients with recurrent and refractory bone 
and soft tissue sarcomas, hypothesizing that the addition 
of temsirolimus will sensitize the  ALDHhigh population 
to the liposomal doxorubicin. Encapsulating doxorubicin 
in pegylated liposomes allows improved localization of 
drug to tumors, resulting in activity in chemotherapy-
refractory disease. Pegylated liposomal doxorubicin is 
generally better tolerated than standard doxorubicin, 
allowing treatment of patients who have already received 
substantial doses of anthracyclines. We have previously 
published the results of the dose finding portion of this 
study [6] and are reporting here the results of the Phase 
II portion of the clinical trial, including pharmacody-
namic data regarding mTOR inhibition and targeting of 
 ALDHhigh sarcoma cells.
Methods
Patient eligibility requirements
Eligible patients were at least 1 year of age, had a histo-
logically confirmed diagnosis of sarcoma that was either 
recurrent or refractory to conventional therapy, and had 
measurable disease amenable to percutaneous image-
guided biopsy. Additionally, patients were required 
to have an adequate performance status (ECOG ≤ 2; 
Karnofsky or Lansky ≥ 60% for children), a life expec-
tancy greater than 3  months, and adequate organ func-
tion (absolute neutrophil count ≥ 1500/µl, platelet 
count ≥ 100,000/µl, total bilirubin ≤ 1.5× institutional 
upper limit of normal, AST and ALT ≤ 2.5× institu-
tional upper limit of normal, and creatinine ≤ 1.5× insti-
tutional upper limit of normal for age or a creatinine 
clearance ≥ 60  ml/min/1.73  m2). Since temsirolimus can 
affect both lipid and glucose metabolism, patients were 
required to have a fasting cholesterol ≤ 350  mg/dl, fast-
ing serum triglycerides ≤ 400  mg/dl, amylase and lipase 
within normal limits (unless elevations were related 
to tumor involving the pancreas), and a hemoglobin 
A1c ≤ 10%. Patients were excluded if they had a history of 
pulmonary hypertension or pneumonitis, prior therapy 
with an mTOR inhibitor, uncontrolled brain metasta-
ses, a history of hypersensitivity to macrolide antibiot-
ics (because of the risk of crossreactions), or grade 3 or 
4 proteinuria. The study was approved by the Johns Hop-
kins University Institutional Review Board and patients 
signed written informed consent according to institu-
tional standards. The trial was registered with Clinical-
Trials.gov (Registration ID: NCT00949325).
Treatment plan
Temsirolimus and liposomal doxorubicin were admin-
istered intravenously in the outpatient clinic, and dos-
ing was based on body surface area to allow concurrent 
enrollment of both children and adults. Temsirolimus 
was given weekly, and liposomal doxorubicin was admin-
istered every 28  days. Patients were pretreated with 
diphenhydramine to avoid infusion-related hypersen-
sitivity reactions. We are reporting here the results of 
18 subjects treated at the recommended phase II dose 
combination of liposomal doxorubicin 30  mg/m2/dose 
monthly with temsirolimus 20 mg/m2/dose weekly. Three 
patients were treated at a higher dose of temsirolimus 
(27 mg/m2 weekly), and they are included in some of the 
analyses as well.
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Treatment efficacy
Subjects were considered evaluable for response if 
they received therapy at least until the first scheduled 
radiologic evaluation. Event-free survival (EFS) and 
progression-free survival (PFS) were determined from 
the date of the first dose of study drug. EFS was defined 
as the time to either documentation of disease progres-
sion or withdrawal from the study due to unacceptable 
toxicity. Subjects who withdrew from the study for rea-
sons other than toxicity or progression were censored 
for EFS on the date of withdrawal. PFS was defined as 
the time to documentation of disease progression as 
defined by RECIST criteria. Subjects who withdrew 
from the study were censored for PFS on the date of 
withdrawal.
Flow cytometry
Patients underwent core needle biopsies at study entry, 
after 4  weeks of therapy, and at the time of progres-
sion. Samples were digested using collagenase/dispase 
as previously described, and single cells isolated using 
a Ficoll gradient. These cells were then treated with 
Aldefluor (Stem Cell Technologies, Vancouver, BC) 
according to the manufacturer’s instructions [6], and 
then separated by flow cytometry using FACSAria and 
FACSDiva software (BD Biosciences, Franklin Lakes, 
NJ) into populations with high aldehyde dehydroge-
nase expression  (ALDHhigh), low expression  (ALDHlow), 
and flow through cells (cells passed through the flow 
cytometer but not sorted).
Immunocytochemistry
Paraffin-embedded tumor samples were deparaffinized 
in xylene and rehydrated in graded alcohol and rinsed 
in 1× PBS. Antigens were retrieved by boiling samples 
for 12 min in citrate buffer, pH 6 (Invitrogen). Nonspe-
cific binding sites were blocked using 1  ml PBS con-
taining 5% goat serum and 1% bovine serum albumin 
(BSA). The sections were incubated overnight at 4  °C 
in a humidor with monoclonal antibody to ALDH1 
(1:100; BD bioscience, clone 44), diluted with 1% goat 
serum, 0.2% BSA and 0.3% Triton X-100 in PBS (pH 
7.4), followed by washing with PBS. Sections were then 
incubated with peroxidase-conjugated secondary anti-
body (Jackson Immunoresearch Laboratories, USA) of 
appropriate specificity. 3,3′-diaminobenzidine (DAB, 
Pierce) was used as substrate for peroxidase and coun-
terstaining was performed with modified Harris hema-
toxylin solution (Sigma). Sections were dehydrated by 
passage through graded alcohol concentrations and 
finally xylene. Cover slips were mounted using DPX 
(Sigma). Completed immunostaining was visualized 
using microscopy (Nikon E600), and photographed 
with digital camera (Nikon DXM1200F; ACT-1 
software).
For immunocytochemical detection of ALDH, cells 
were pelleted on slides using a cytospin. Cells were fixed 
with 4% paraformaldehyde for 20 min at room tempera-
ture, washed with PBS, and blocked in PBS with normal 
goat serum for 1  h at room temperature. After block-
ing, cells were stained overnight with primary antibody 
against ALDH1 (BD Bioscience, clone 44)) at a 1∶100 
dilution in PBS with 5% normal goat serum and 0.02% 
Triton X-100 at 4  °C. The next day, cells were washed 
with PBS and stained with Alexa Fluor 555 goat anti-
mouse antibody (Invitrogen) at 1:400 dilution. After sec-
ondary labeling, cells were washed in PBS and mounted 
in Prolong Gold with DAPI.
Analysis of ALDH immunohistochemical staining
Quantification of ALDH expression was performed using 
FRIDA [FRamework for Image Dataset Analysis; [3], a 
custom open source image analysis software package 
(available at http://sourc eforg e.net/proje cts/frida jhu/)] 
for the analysis of RGB color images generated from 
scanning of tissue microarray slides. Hue Saturation and 
Brightness (HSB) segmentation ranges for DAB brown 
staining and hematoxylin alone (cells not staining brown) 
were defined by creating different color masks. Num-
bers of cells were counted by using particle count filter 
set with size limitation. The percentage of ALDH-pos-
itive cells were calculated by using the number of DAB 
labeled cells divided by the sum of the DAB labeled and 
the hematoxylin labeled cells ×100.
Statistical analysis
Data were analyzed using Prism 5.0 software (GraphPad, 
Inc., La Jolla, CA).
Results
Patient characteristics
This trial was a phase I/II study of temsirolimus and 
liposomal doxorubicin for patients with relapsed or 
refractory soft tissue and bone sarcomas. The results 
of the phase I portion of the study have been previ-
ously reported [6]. In the phase II portion of the study, 
a total of 18 subjects were treated at the recommended 
phase II dose (RP2D), liposomal doxorubicin 30 mg/m2/
dose monthly with temsirolimus 20 mg/m2/dose weekly 
(Table  1). In addition, 3 subjects were treated with a 
higher dose of temsirolimus, 27  mg/m2/dose weekly 
as part of the dose escalation phase. Of the 18 subjects 
treated at the RP2D, 15 were evaluable for response, as 
were all of the subjects treated at the higher dose. Of the 
three unevaluable patients, one withdrew after 20 days of 
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therapy because of stomatitis, one was removed from the 
study after 7 days because of persistent Grade 3 elevation 
of ALT, and one withdrew after 7 days due to clinical dete-
rioration. Seven of the subjects treated at the RP2D were 
male and eleven were female. Median age was 27  years 
(range 9–70). Two of the subjects treated at the higher 
dose were female (ages 57 and 59), and the other was a 
10 year old boy. The subjects had a number of sarcoma 
types, including rhabdomyosarcoma (n = 5), leiomyo-
sarcoma (n = 3), synovial sarcoma (n = 2), mesenchymal 
chondrosarcoma (n = 2), and a variety of others (detailed 
in Table 1). Of the 18 subjects treated at the RP2D, 1 had 
primary refractory disease, 3 were treated at first relapse, 
6 were treated after failure of second line therapy, 6 were 
treated at second relapse, and 2 were treated after failure 
of third-line therapy. Two of the subjects at the higher 
dose level were treated during first relapse after failure of 
second line therapy, and one was multiply recurrent after 
surgeries but had no prior systemic therapy. Fourteen of 
the subjects, including 2 treated at the higher dose, had 
previously received doxorubicin.
Response to treatment
The primary endpoint of the phase II portion of this 
study was PFS. Although eighteen patients were treated 
at the RP2D, 3 were unevaluable as described above. 
Out of the 15 patients treated at the RP2D who were 
evaluable for response, 8 terminated therapy due to 
radiographic progression of disease, 5 withdrew due to 
clinical deterioration, 1 withdrew because of toxicity, 
and 1 withdrew due to a need to discontinue treatment 
to allow surgery for an unrelated medical condition. 
The median PFS for this population was 315  days 
(range 27–799), with the patients who discontinued 
therapy for reasons other than disease progression cen-
sored at the time of discontinuation (Fig.  1a). Median 
EFS (discontinuation for clinical deterioration consid-
ered an event) was 75  days (Fig.  1a). Including the 3 
subjects treated at the higher dose of temsirolimus in 
the analysis, median PFS was unchanged at 315  days 
(range 27–799), but median EFS was longer at 119 days 
(Fig. 1b). Response rate, defined as stable disease (SD) 
or better for 60 days (2 cycles) was 53% (8 of 15) at the 
RP2D and 56% (10 of 18) including the subjects treated 
with the higher dose of temsirolimus. A waterfall plot 
of best responses, using RECIST 1.1 criteria, shows 3 
patients had progressive disease (PD) at their first eval-
uation (20%), 2 patients had a partial response (PR) as 
best response (13%), and the remainder had stable dis-
ease (SD) as their best response (Fig.  1c). Those who 
Table 1 Patient characteristics
MFH Malignant fibrous histiocytoma, MPNST Malignant peripheral nerve sheath tumor, HGUPS High grade undifferentiated pleiomorphic sarcoma, RR refractory 
relapse, Patients in italics were treated at the higher dose of temsirolimus (Dose Level 5)
Patient Age Gender Diagnosis Status Evaluable? Prior Doxo
1 19 M Mesenchymal Chondrosarcoma RR 1 N Y
2 43 F MFH RR 1 Y Y
3 39 F Leiomyosarcoma Relapse 2 Y Y
4 18 M Rhabdomyosarcoma Relapse 1 Y N
5 9 F Rhabdomyosarcoma RR 2 Y N
6 20 F Rhabdomyosarcoma Relapse 1 N Y
7 63 F Leiomyosarcoma Relapse 2 Y Y
8 21 M Rhabdomyosarcoma RR 1 Y Y
9 70 M Spindle Cell Sarcoma Relapse 2 Y N
10 59 F Leiomyosarcoma RR 1 Y Y
11 57 F Chondrosarcoma Mult Relapse Y N
12 10 M Osteosarcoma RR 1 Y Y
13 43 F Clear Cell Sarcoma Relapse 2 Y N
14 16 M Ewing Sarcoma RR 1 Y Y
15 68 F Leiomyosarcoma RR 1 N N
16 57 F Synovial Sarcoma RR 2 Y Y
17 22 F Mesenchymal Chondrosarcoma Relapse 2 Y Y
18 32 M MPNST Relapse 2 Y Y
19 20 F HGUPS RR 1 Y Y
20 21 F Epithelioid Sarcoma Relapse 1 Y Y
21 42 M Rhabdomyosarcoma Refractory Y N
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responded to therapy (defined as SD or better at first 
evaluation) tended to have prolonged responses, with a 
median PFS for this group of 358 days (range = 75–799) 
and median EFS of 249 days.
As noted in Table  1, 9 of 15 subjects treated at the 
RP2D, and 2 of 3 treated at the higher dose, had pre-
viously been exposed to doxorubicin (11 of 18 = 61%). 
PFS among the subjects previously treated with doxo-
rubicin was 108  days (range 27–358) and EFS was 
49  days, both substantially shorter than the popula-
tion as a whole, though because of the small sam-
ple size the difference was not statistically significant 
(Fig.  2). Response rate in this group was also worse 
than the population as a whole (4 of 11 = 36%). For 
the group of patients with prior doxorubicin exposure 
who responded to therapy, however, response was pro-
longed, with median PFS of 315  days (range = 160–
358), comparable to the PFS of responders within the 
entire study population.
Toxicities
Subjects were treated for a median of 2 cycles (mean 
number of cycles 5.5, range 0–24). This was a heavily 
pretreated group of patients, with a median of 2 prior 
lines of systemic therapy (range 0–6). Despite this bur-
den of prior therapy, treatment was reasonably well tol-
erated. At the RP2D (dose level 4: temsirolimus 20  mg/
m2/dose weekly), we observed forty AEs of grade 3 or 
4 with “possible” or greater attribution, thirty-three 
grade 3 and seven grade 4 (Table 2). Thrombocytopenia 
and hypophosphatemia were the most common severe 
adverse events (grade 3 or higher) with six incidences 
of each, followed by five incidences of grade 3 neutro-
penia. There were three episodes each of ALT elevation 
(all grade 3), lipase elevation (all grade 4), and vomiting 
(all grade 3), two instances each of hypokalemia (grade 
3) and amylase elevation (grade 3). Single incidences of 
grade 3 increased AST, bone infection, hypocalcemia, 
hyponatremia, stomatitis, white blood cell decreased, 
lymphocyte count decreased, and weight loss were 
reported. In the three patients treated at the higher dose 
of temsirolimus, (dose level 5: 27  mg/m2/dose weekly), 
two incidences of grade 3 hypophosphatemia and eme-
sis were reported, as well as single incidences of grade 
3 hypokalemia, neutropenia, and abdominal pain, and 
a single incidence of grade 4 anorexia. One patient died 
while on study, attributed to progression of disease, not 
study drug.
Weight loss can be a surrogate for overall health in 
patients undergoing anti-cancer therapy, and mTOR 
inhibition has the potential to alter the metabolism of 
both normal and cancer cells. We therefore investigated 
changes in body weight during treatment. Of 15 evalu-
able subjects treated at the RP2D, three (21%) never lost 
weight (treated for 2, 4, and 6 cycles). Seven subjects lost 
weight during the course of therapy (50%), but lost < 10% 
Fig. 1 a Event‑Free Survival (EFS) and Progression‑free Survival (PFS) of the 15 patients treated at the RP2D. A Kaplan–Meier curve indicating the 
time from beginning of treatment to withdrawal from study (EFS) or beginning of treatment to first objective evidence of disease progression by 
RECIST 1.1 criteria (PFS). b EFS and PFS of the 18 patients treated at the RP2D and the dose level above. A Kaplan–Meier curve indicating the time 
from beginning of treatment to withdrawal from study (EFS) or beginning of treatment to first objective evidence of disease progression by RECIST 
(PFS). c A waterfall plot of the best responses for the 15 patients treated at R2PD
Fig. 2 Progression‑Free Survival of subjects who had previously 
received doxorubicin compared with the entire study population. A 
Kaplan–Meier curve indicating the PFS of the 11 subjects who had 
previously received doxorubicin compared with the PFS of the total 
population of subjects
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of their starting body weight, and 3 of these regained 
weight from their minimum while continuing on treat-
ment. The remaining 5 (29%) lost 10% or more of their 
initial body weight, but even among this group, one 
regained weight from her minimum while continuing on 
treatment (Fig. 3).
Another surrogate for overall heath is performance sta-
tus. All 15 evaluable subjects treated at the RP2D started 
treatment with an ECOG performance status of 0 or 1. Of 
these, only 5 (33%) had a worsening of performance sta-
tus of two or more levels during treatment: one patient’s 
performance status declined from 0 to 2, two from 1 to 3, 
and two from 0 to 3. In each of these cases, the fall in per-
formance status was temporally associated with tumor 
growth, suggesting that disease progression, rather than 




We evaluated mTOR signaling by immunohistochemical 
analysis of phosphorylated S6 kinase (pS6K; reflecting 
target of rapamycin complex 1 [TORC1] signaling) and 
phosphorylated AKT (pAKT; reflecting TORC2 signal-
ing) using archived tumor biopsy samples at the time of 
diagnosis (baseline). In addition, subjects underwent an 
optional biopsy at week 4 of therapy, and for some sub-
jects at study entry (1 subject) and at the end of the study 
(4 subjects). Single cells suspensions were made from this 
biopsy material, and cells were isolated based on ALDH 
expression and analyzed by immunocytochemistry for 
pS6K and pAKT staining. Total S6K and AKT stain-
ing served as an internal control. Out of the 12 subjects 
treated at the RP2D who had evaluable biopsies at week 
Table 2 Adverse events
Only adverse events (AEs) of Grade ≥ 3 and with attribution of “Possible” or above reported. ALT alanine aminotransferase, AST aspartate aminotransferase, ANC 
absolute neutrophil count
Group Toxicity Grade 3 Grade 4 Total Dose level
Hematologic Thrombocytopenia 3 3 6 4
Neutropenia 5 – 5 4
Lymphocyte count decreased 1 – 1 4
White blood cell decreased 1 – 1 4
Gastrointestinal Lipase increased – 3 3 4
ALT increased 3 – 3 4
Vomiting 3 – 3 4, 5
Serum Amylase increased 2 – 2 4
Abdominal pain 1 – 1 5
Anorexia – 1 1 5
AST increased 1 – 1 4
Stomatitis 1 – 1 4
Weight loss 1 – 1 4
Metabolic Hypophosphatemia 6 – 6 4, 5
Hypokalemia 2 – 2 4, 5
Hypocalcemia 1 – 1 4
Hyponatremia 1 – 1 4
Other Bone infection 1 – 1 4
Fig. 3 Spaghetti plot of patient weights during treatment. Each line 
represents an individual patient and the number of cycles of therapy 
is indicated on the Y axis
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4, 8 (67%) were concordant for TORC1 inhibition and 
response, and 9 were concordant for TORC2 inhibition 
and response (Fig. 4). Though not statistically significant 
because of the small sample size (p-values of 0.61 and 
0.13 respectively), pAKT inhibition has a positive predic-
tive value (PPV) and negative predictive value (NPV) of 
71.3% and 74.7% respectively.
One illustrative case is subject 16. This was a 43-year-
old woman with metastatic clear cell sarcoma who was 
treated at 3rd relapse. Her only prior therapy had been 
surgery. She underwent biopsy at the time of treatment 
initiation, and 29% of her  ALDHhigh cells stained for 
pS6K and 100% stained for pAKT. In addition, 43% of 
her  ALDHlow cells stained for pS6K and 43% stained for 
pAKT. At week 4, no  ALDHhigh cells stained for pS6K 
or for pAKT, and only 8% of her  ALDHlow cells stained 
for pS6K, with 27% staining for pAKT. This significant 
reduction in mTOR signaling correlated with a prolonged 
period of progression-free survival (752 days).
Targeting stem cells
The rationale for this study was our in  vitro observa-
tion that mTOR inhibition increases the sensitivity of 
sarcoma stem cells to chemotherapy and our hypothesis 
that eliminating CSC would translate into improved sur-
vival. Three patients had evaluable paired tumor biopsy 
samples to assess the effect of the treatment on the per-
centage of  ALDHhigh cells. Patient 8 and 11 each had a 
rhabdomyosarcoma that did not respond to the tem-
sirolimus/liposomal doxorubicin therapy, and had biop-
sies at weeks 4 and 8 that demonstrated an increase in 
 ALDHhigh percentage, from 2 to 43.9% and 0.6 to 52.3% 
respectively. Patient 16, however, who had a metastatic 
Clear Cell Sarcoma, had biopsies at baseline and week 
4 that demonstrated a decrease in  ALDHhigh percent-
age from 29.6 to 3.7%. This patient did show a response 
to therapy and had a 752-day progression free interval. 
While these numbers are small, they are supportive of 
our hypothesis that eliminating the  ALDHhigh population 
is imperative to curing the disease.
Discussion
The survival rate for several sarcomas has plateaued in 
recent years despite attempts to intensify chemotherapy. 
Particularly, the survival rates for sarcoma patients who 
present with metastatic disease or who have relapsed 
disease have not seen significant improvement in dec-
ades [7, 8]. One possible explanation for this may be the 
existence of small subpopulations of sarcoma cells that 
are resistant to conventional chemotherapy and are able 
to cause recurrences and metastases. We have previously 
shown that high expression of ALDH can act as a marker 
for Ewing sarcoma cells that demonstrate “stem cell-like” 
properties including resistance to conventional chemo-
therapy. Similar findings have been shown with other 
sarcoma histologies [3–5]. We have shown in preclinical 
testing that  ALDHhigh cells are resistant to chemotherapy 
agents commonly used to treat sarcomas, such as doxo-
rubicin, and that inhibition of the mTOR pathway with 
agents such as rapamycin can overcome this chemore-
sistance seen in the  ALDHhigh cells.
Clinical trials in sarcoma with single agent mTOR 
inhibitors have shown modest efficacy at best [9, 10]. 
While a degree of cytotoxicity from mTOR inhibition can 
be seen, mTOR inhibition combined with conventional 
chemotherapeutic agents has yielded more promising 
results [11]. The mechanism by which mTOR inhibition 
enhances the efficacy of chemotherapy, however, has not 
been fully elucidated. Our study was designed to evaluate 
the ability of mTOR inhibition to overcome the chemore-
sistance of relapsed sarcomas and in particular the resist-
ance seen in  ALDHhigh populations within these tumors. 
We report the phase II portion of a phase I/II trial testing 
temsirolimus in combination with liposomal doxorubicin 
in patients with relapsed or refractory sarcomas. Our 
patient population was heavily pretreated, but despite 
Fig. 4 Correlation between mTOR inhibition and response to therapy. Cells obtained from a core biopsy at week 4 were stained for either pS6K (a) 
or pAKT (b), and compared with staining from the diagnostic biopsy. Inhibition of phosphorylation was compared with response or nonresponse to 
treatment
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this, the patients tolerated the study regimen well. While 
interpretation of our results is limited by a small number 
of patients and comparison to historical controls, of the 
evaluable patients at our RP2D, PFS was approximately 
three times longer with the combination of liposomal 
doxorubicin and temsirolimus than what has been seen 
in similar patients treated with single agent mTOR inhib-
itor [9]. The PFS observed was also at least two times 
longer than that reported in similar patients treated with 
liposomal doxorubicin alone or combined with other 
conventional chemotherapy drugs [12, 13]. The response 
rate (stable disease or better for 2 cycles) in our study was 
consistent with other studies of relapsed sarcoma com-
bining chemotherapy with mTOR inhibition as were the 
incidence and severity of adverse events observed [11]. 
To our knowledge, while not the first study to test mTOR 
inhibition combined with chemotherapy in sarcomas, 
this is the first study where the effect of the combination 
specifically on a putative CSC population was assessed. 
Though further limited by the small number of patients 
for whom pre- and post-treatment tumor biopsy samples 
were available for analysis, response to therapy correlated 
with reduction in the  ALDHhigh population.
Recently, Mu et  al. [14] showed in murine osteosar-
coma cell lines that ALDH activity is dependent on 
mTOR activity. While this was a single small in  vitro 
study on murine cell lines, it raises the possibility that 
the chemosensitizing effect of mTOR inhibition seen in 
this and other trials could be due to direct inhibition of 
ALDH. There is increasing evidence that, in addition to 
being a marker for CSCs, ALDH may play an active role 
in providing CSCs their “stemness”, particularly contrib-
uting to the chemoresistance seen in these cells. ALDH 
is a superfamily of phase I oxidizing enzymes responsible 
for detoxification of aldehydes [2]. ALDH is implicated in 
cellular “self-protection,” including supporting antioxi-
dant factors countering the production of reactive oxygen 
species [15]. It is also known to inactivate chemotherapy 
drugs, the most recognized being cyclophosphamide and 
related agents, but also doxorubicin, cisplatin, temozo-
lemide and taxanes, which are many of the cornerstones 
of sarcoma therapy. Furthermore, evidence supporting 
the importance of ALDH expression in the process of 
metastasis is emerging in several solid tumors includ-
ing osteosarcoma, where the ALDH inhibitor disulfiram 
appears to inhibit metastatic disease [16, 17].
While the mTOR pathway plays several roles in can-
cer cell biology, including resistance to apoptosis and 
metabolic reprogramming, this association with ALDH 
expression and the emerging evidence of a functional 
role for ALDH highlights a potential new target for 
overcoming chemoresistance. The fields of breast and 
colon cancer research, among others, are exploring 
these approaches, and evidence would suggest sarcoma 
research should follow suit. Targeting the mTOR pathway 
to treat sarcomas is already underway. Targeting ALDH 
directly or in combination with mTOR blockade holds 
additional promise. Finally, the development of resistance 
to mTOR inhibition has been well described [18, 19]. 
Further studies in how this resistance develops, and tech-
niques to prevent or overcome this resistance are neces-
sary for the success of this treatment strategy.
Conclusions
Within the confines of this small phase I/II study with 
a heterogeneous patient population, the combination 
of temsirolimus with liposomal doxorubicin is safe and 
well tolerated, and PFS is better than previously reported 
with either agent given alone. Response to treatment cor-
relates with laboratory evidence of a reduction in the 
 ALDHhigh population of putative sarcoma stem cells, vali-
dating the concept that targeting this specific population 
of cells can improve treatment outcomes.
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